Presented by: Michael T. Milano, MD, PhD, DABR & Tithi Biswas, MD
May 15, 2017
1:00pm ET

Advances in stereotactic radiotherapy planning and delivery have facilitated the treatment of discrete lesions with non-invasive ablative therapy. Stereotactic body radiotherapy (SBRT) is associated with high rates of tumor control and low toxicity. SBRT has been increasingly used to treat patients with limited metastatic disease. The clinical state of metastases, limited in number and extent, has been coined “oligometastases.” A select number patients with oligometastases experience long disease-free intervals after SBRT- similar to those seen after surgical resection. Ongoing studies are seeking to determine the extent of benefit of SBRT in the treatment of oligometastases. These studies hope to better identify appropriate candidates, and assist in integrating SBRT into management strategies for specific diseases